export const blogPosts = [
    {
        id: "1",
        title: "Lenacapavir: Revolutionary HIV Prevention Drug Shows 100% Efficacy",
        description: "Science's 2024 Breakthrough of the Year: A twice-yearly injection that achieved unprecedented 96-100% efficacy in preventing HIV infection in clinical trials.",
        date: "2024-12-12",
        category: "Infectious Disease",
        image: "https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?w=1200&h=600&fit=crop",
        content: `
            <p>In a landmark achievement recognized by Science as the 2024 Breakthrough of the Year, lenacapavir has emerged as a game-changing HIV prevention tool. This injectable medication requires administration only twice a year and has demonstrated unprecedented efficacy in preventing HIV infection.</p>

            <h2>Clinical Trial Results</h2>
            <p>Two major Phase 3 clinical trials demonstrated remarkable effectiveness:</p>
            <ul>
                <li><strong>PURPOSE-1 Trial:</strong> Conducted with cisgender women in Uganda and South Africa, not a single participant taking lenacapavir contracted HIV, representing a 96-100% reduction compared to background risk.</li>
                <li><strong>PURPOSE-2 Trial:</strong> Among men and gender-diverse individuals across six countries, only two out of thousands taking lenacapavir contracted HIV, showing 82-99% efficacy.</li>
            </ul>

            <h2>The Science Behind Lenacapavir</h2>
            <p>Lenacapavir works by targeting HIV's capsid protein, which forms a protective shell around the virus's genetic material. The drug is stored in fat tissue and slowly released over months, providing protection for at least six months.</p>

            <h2>Global Impact</h2>
            <p>Regulatory approval is expected by mid-2025. Gilead Sciences has partnered with six generic manufacturers to produce low-cost versions for 120 developing countries.</p>
        `,
    },
    {
        id: "2",
        title: "Blood Test Achieves 90% Accuracy in Alzheimer's Detection",
        description: "Stanford and NIH researchers develop PrecivityAD2, a blood test that can identify Alzheimer's disease with approximately 90% accuracy.",
        date: "2024-11-15",
        category: "Neurology",
        image: "https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=600&fit=crop",
        content: `
            <p>A major breakthrough in Alzheimer's disease diagnostics emerged in 2024 with the development of a blood test that can identify the disease with approximately 90% accuracy.</p>

            <h2>The PrecivityAD2 Test</h2>
            <p>The new blood test, called PrecivityAD2, measures the ratio of multiple key biomarkers of Alzheimer's disease present in the blood. In a large clinical trial involving older adults, the test correctly identified Alzheimer's disease in about 90% of cases.</p>

            <h2>Impact on Patient Care</h2>
            <ul>
                <li><strong>Earlier Diagnosis:</strong> The simple blood test enables screening of at-risk individuals long before symptoms become severe.</li>
                <li><strong>Treatment Planning:</strong> Early detection allows patients to start treatment with newly approved Alzheimer's medications sooner.</li>
                <li><strong>Increased Access:</strong> The non-invasive nature and lower cost make diagnostic testing accessible to a much larger population.</li>
            </ul>
        `,
    },
    {
        id: "3",
        title: "First New Schizophrenia Drug Mechanism in Decades Shows Promise",
        description: "Xanomeline-trospium becomes the first FDA-approved schizophrenia medication with a novel mechanism of action in over 50 years.",
        date: "2024-10-28",
        category: "Psychiatry",
        image: "https://images.unsplash.com/photo-1559757175-5700dde675bc?w=1200&h=600&fit=crop",
        content: `
            <p>For the first time in over five decades, psychiatry has a fundamentally new approach to treating schizophrenia. Xanomeline-trospium, approved by the FDA in 2024, represents a paradigm shift in how we address this complex condition.</p>

            <h2>A New Mechanism</h2>
            <p>All previous antipsychotic medications primarily worked by blocking dopamine receptors. Xanomeline-trospium takes an entirely different approach by targeting muscarinic acetylcholine receptors.</p>

            <h2>Addressing Traditional Side Effects</h2>
            <p>One of the most significant advantages is its side effect profile. Traditional antipsychotics often cause movement disorders, weight gain, and metabolic changes. Xanomeline-trospium lacks these side effects, making it easier for patients to tolerate long-term treatment.</p>
        `,
    },
    {
        id: "4",
        title: "World's First Successful Whole Eye Transplant",
        description: "NYU Langone surgeons achieve unprecedented success in whole-eye transplantation, with the eye maintaining normal structure and blood flow.",
        date: "2024-09-20",
        category: "Ophthalmology",
        image: "https://images.unsplash.com/photo-1582719471137-c3967ffb1c42?w=1200&h=600&fit=crop",
        content: `
            <p>NYU Langone Health surgeons successfully performed the world's first whole-eye transplant combined with a partial face transplant. Six months post-surgery, the transplanted eye maintains its normal shape, blood flow, and retinal health.</p>

            <h2>Defying Expectations</h2>
            <ul>
                <li><strong>Structural Integrity:</strong> The eye has retained its normal shape and size.</li>
                <li><strong>Blood Flow:</strong> The eye's vascular system remains healthy and functional.</li>
                <li><strong>Retinal Health:</strong> The retina shows no signs of deterioration.</li>
            </ul>

            <h2>Future Goals</h2>
            <p>While the surgery didn't restore vision, the organ's ongoing health represents tremendous progress toward that ultimate goal. NYU has joined a national effort that received $56 million in funding to achieve vision-restoring whole-eye transplants.</p>
        `,
    },
    {
        id: "5",
        title: "Ketogenic Diet Shows Benefits for Severe Mental Illness",
        description: "Stanford Medicine research demonstrates that a ketogenic diet can effectively treat severe mental illnesses while addressing metabolic side effects from medications.",
        date: "2024-08-15",
        category: "Psychiatry",
        image: "https://images.unsplash.com/photo-1490645935967-10de6ba17061?w=1200&h=600&fit=crop",
        content: `
            <p>Stanford Medicine researchers have discovered that a ketogenic diet can significantly improve severe mental illness symptoms in patients with schizophrenia and bipolar disorder while simultaneously addressing metabolic complications from antipsychotic medications.</p>

            <h2>Study Findings</h2>
            <p>Participants showed improvements in multiple areas:</p>
            <ul>
                <li>Meaningful reductions in hallucinations, delusions, and mood instability</li>
                <li>Improvements in weight, blood sugar control, and cholesterol levels</li>
                <li>Reversal of common medication-induced metabolic problems</li>
            </ul>

            <h2>How It Works</h2>
            <p>The ketogenic diet induces ketosis, where the body burns fat for fuel instead of glucose. This metabolic shift has beneficial effects on brain function including improved energy metabolism and reduced neuroinflammation.</p>
        `,
    },
    {
        id: "6",
        title: "AI-Powered Home OCT Device Revolutionizes Retinal Monitoring",
        description: "FDA approves the first home-use optical coherence tomography device with autonomous AI, enabling remote retinal disease monitoring.",
        date: "2024-07-10",
        category: "Ophthalmology",
        image: "https://images.unsplash.com/photo-1581591524425-c7e0978865fc?w=1200&h=600&fit=crop",
        content: `
            <p>The FDA's 2024 approval of the first home-use OCT device represents a transformative advance in retinal disease management, combining cutting-edge imaging technology with autonomous artificial intelligence.</p>

            <h2>Autonomous AI Integration</h2>
            <ul>
                <li><strong>Guides Image Acquisition:</strong> Helps patients capture high-quality scans without technical expertise</li>
                <li><strong>Analyzes Images Immediately:</strong> Uses deep learning to detect signs of disease progression</li>
                <li><strong>Provides Real-Time Feedback:</strong> Alerts patients and physicians when concerning changes are detected</li>
            </ul>

            <h2>Clinical Applications</h2>
            <p>Particularly valuable for monitoring age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.</p>
        `,
    },
    {
        id: "7",
        title: "Breakthrough Drug Protects Children with Food Allergies",
        description: "Stanford Medicine study shows omalizumab injections enable children with severe food allergies to safely tolerate small amounts of allergens.",
        date: "2024-06-25",
        category: "Immunology",
        image: "https://images.unsplash.com/photo-1505751172876-fa1923c5c528?w=1200&h=600&fit=crop",
        content: `
            <p>A Stanford Medicine-led study has demonstrated that omalizumab can protect children with severe food allergies from dangerous reactions to accidental exposures.</p>

            <h2>Study Results</h2>
            <p>Children receiving regular injections of omalizumab could safely ingest small amounts of their allergensâ€”amounts typically encountered during accidental exposure. Key findings include:</p>
            <ul>
                <li>Significant reduction in allergic reaction severity</li>
                <li>Increased threshold for triggering reactions</li>
                <li>Protection across multiple food allergens simultaneously</li>
            </ul>

            <h2>Multi-Allergen Protection</h2>
            <p>Unlike allergen-specific immunotherapy, omalizumab provides protection against multiple allergens simultaneously including peanuts, tree nuts, milk, eggs, and shellfish.</p>
        `,
    },
    {
        id: "8",
        title: "Brain-Computer Interface Restores Speech for Paralyzed Patient",
        description: "UC Davis and BrainGate research enables a paralyzed man to speak naturally using his own voice through an advanced brain-computer interface.",
        date: "2024-05-30",
        category: "Neurotechnology",
        image: "https://images.unsplash.com/photo-1559757148-5c350d0d3c56?w=1200&h=600&fit=crop",
        content: `
            <p>Researchers at UC Davis and the BrainGate consortium have enabled Casey Harrell, who lost the ability to speak due to ALS, to communicate fluently using a brain-computer interface that converts his neural signals directly into speech.</p>

            <h2>How the System Works</h2>
            <ul>
                <li><strong>Neural Implants:</strong> Electrode arrays placed on the brain's speech motor cortex</li>
                <li><strong>AI Decoding:</strong> Machine learning algorithms recognize patterns associated with specific speech sounds</li>
                <li><strong>Speech Synthesis:</strong> AI generates speech using Harrell's own voice from old recordings</li>
            </ul>

            <h2>Unprecedented Accuracy</h2>
            <p>The system worked immediately upon first use and achieved accuracy exceeding any previously reported communication BCI.</p>
        `,
    },
];